myriamed offers a two-tiered phenotypic screening approach. This includes a primary screen in a proprietary 48-cell format followed by result verification using classical organ bath measurements under isometric conditions. Endpoints include force, beating rate and rhythm, contraction kinetics and many more. Please contact us for further details. The myrScreen strategy is adapted according to the specific needs of our customers.
myrScreen-Cardio
myrScreen-Cardio is a human 48-well platform that allows analyses of function and dysfunction as well as regeneration and degeneration in engineered human hearts.
For more information see also:
Defined Engineered Human Myocardium with Advanced Maturation for Applications in Heart Failure Modelling and Repair.
myrScreen-Skeletal
myrScreen-Skeletal allows the simultaneously analyses of function and dysfunction as well as regeneration and degeneration in 48 engineered human skeletal muscle models.
For more information see also:
Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy.
myrScreen-Connective Tissue
myrScreen-Connective Tissue for stroma function and dysfunction screens including screens for antifibrotic drugs.
For more information see also:
Using different geometries to modulate the cardiac fibroblast phenotype and the biomechanical properties of engineered connective tissues.
myrScreen-Brain
myrScreen-Brain allows the simultaneously analyses of function and dysfunction as well as regeneration and degeneration assayed on multi-electrode arrays.
For more information see also:
Developmental GABA polarity switch and neuronal plasticity in Bioengineered Neuronal Organoids.
Products
